谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Pilot Study of Bevacizumab in Combination with Docetaxel and Cyclophosphamide As Adjuvant Treatment for Patients with Early Stage HER-2 Negative Breast Cancer, Including Analysis of Candidate Circulating Markers of Cardiac Toxicity: ICORG 08–10 Trial

Giuseppe Gullo,Alex J. Eustace,Alexandra Canonici,Denis M. Collins, Michael J. Kennedy,Liam Grogan,Oscar Breathhnach,John McCaffrey,Maccon Keane,Michael J. Martin,Rajnish Gupta,Gregory Leonard,Miriam O'Connor,Paula M. Calvert,Paul Donnellan,Janice Walshe,Enda McDermott,Kathleen Scott,Andres Hernando,Imelda Parker,David W. Murray,Alice C. O'Farrell,Ashwini Maratha,Patrick Dicker,Mairin Rafferty,Verena Murphy,Norma O'Donovan,William M. Gallagher,Bonnie Ky,Dimitrios Tryfonopoulos,Brian Moulton,Annette T. Byrne,John Crown

Therapeutic Advances in Medical Oncology（2019）

引用 11|浏览95
暂无评分
关键词
bevacizumab,breast cancer,cardiotoxicity biomarker,docetaxel,cyclophosphamide
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要